JP2010507639A - 癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体 - Google Patents

癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体 Download PDF

Info

Publication number
JP2010507639A
JP2010507639A JP2009533934A JP2009533934A JP2010507639A JP 2010507639 A JP2010507639 A JP 2010507639A JP 2009533934 A JP2009533934 A JP 2009533934A JP 2009533934 A JP2009533934 A JP 2009533934A JP 2010507639 A JP2010507639 A JP 2010507639A
Authority
JP
Japan
Prior art keywords
amino
cyclopentyl
ethyl
methyl
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507639A5 (enExample
Inventor
モファット，デビッド，フェストゥス，チャールズ
パテル，サンジェイ，ラティラル
デイビス，ステファン，ジョン
ベーカー，ケネス，ウイリアム，ジョン
フィリップス，オリバー，ジェームス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of JP2010507639A publication Critical patent/JP2010507639A/ja
Publication of JP2010507639A5 publication Critical patent/JP2010507639A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009533934A 2006-10-25 2007-10-19 癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体 Withdrawn JP2010507639A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2010507639A true JP2010507639A (ja) 2010-03-11
JP2010507639A5 JP2010507639A5 (enExample) 2010-12-02

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533934A Withdrawn JP2010507639A (ja) 2006-10-25 2007-10-19 癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体

Country Status (13)

Country Link
US (1) US20100216802A1 (enExample)
EP (1) EP2079743B1 (enExample)
JP (1) JP2010507639A (enExample)
KR (1) KR20090071668A (enExample)
AT (1) ATE542820T1 (enExample)
AU (1) AU2007310604B2 (enExample)
BR (1) BRPI0718120A2 (enExample)
CA (1) CA2665736A1 (enExample)
EA (1) EA200900593A1 (enExample)
IL (1) IL198082A0 (enExample)
MX (1) MX2009004244A (enExample)
NZ (1) NZ577153A (enExample)
WO (1) WO2008050096A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022504601A (ja) * 2018-10-12 2022-01-13 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ Ｍｓｔ１キナーゼ阻害剤及びその使用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
US8962825B2 (en) * 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
KR20110039278A (ko) 2008-06-23 2011-04-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
CN102076691A (zh) * 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US20120220603A1 (en) * 2009-09-04 2012-08-30 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
HRP20171320T1 (hr) 2012-10-17 2017-10-20 Macrophage Pharma Limited Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117055A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022504601A (ja) * 2018-10-12 2022-01-13 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ Ｍｓｔ１キナーゼ阻害剤及びその使用
JP7130123B2 (ja) 2018-10-12 2022-09-02 中国科学院合肥物質科学研究院 Ｍｓｔ１キナーゼ阻害剤及びその使用

Also Published As

Publication number Publication date
KR20090071668A (ko) 2009-07-01
AU2007310604B2 (en) 2012-02-02
CA2665736A1 (en) 2008-05-02
US20100216802A1 (en) 2010-08-26
IL198082A0 (en) 2009-12-24
EP2079743B1 (en) 2012-01-25
NZ577153A (en) 2012-02-24
EA200900593A1 (ru) 2010-06-30
AU2007310604A1 (en) 2008-05-02
EP2079743A1 (en) 2009-07-22
WO2008050096A1 (en) 2008-05-02
MX2009004244A (es) 2009-05-14
BRPI0718120A2 (pt) 2013-11-12
ATE542820T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
EP2079743B1 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
CN110312719B (zh) 作为jak家族激酶抑制剂的咪唑并吡咯并吡啶
CN101273030B (zh) 丙型肝炎病毒的大环抑制剂
CN106061976B (zh) 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
US9428464B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20100004250A1 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
CN106496209B (zh) 用作atr激酶抑制剂的化合物
US11267825B2 (en) Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
US8178575B2 (en) Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase IV
US20110190306A1 (en) Inhibitors of PLK
WO2008053157A1 (en) Aminoheteroaryl compounds as for the treatment of diseases mediated by c-met kinase activity
KR20130113950A (ko) Ｍｔｏｒ 선택적 키나아제 억제제
CN102395584A (zh) 用于代谢疾病治疗的化合物
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
JP2022512870A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規尿素６，７－ジヒドロ－４ｈ－ピラゾロ［１，５－ａ］ピラジン
US20220363686A1 (en) Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3134396B1 (en) Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CN101541800A (zh) 用于治疗癌症的作为plk抑制剂的蝶啶衍生物
JP2023549187A (ja) 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体
US20220227785A1 (en) Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2009141575A1 (en) Inhibitors of plk
KR20250026777A (ko) 3-(페닐설포닐)-[1,2,3]트리아졸로[1,5a]퀴나졸린-5(4h)-온 유도체
WO2025218831A2 (zh) 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用
CA2965813A1 (en) Spirocyclic containing compounds and pharmaceutical uses thereof
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101014

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120406